Virax Other Current Liab from 2010 to 2024

VRAX Stock  USD 1.94  0.06  3.19%   
Virax Biolabs Other Current Liabilities yearly trend continues to be fairly stable with very little volatility. Other Current Liabilities will likely drop to about 60 K in 2024. During the period from 2010 to 2024, Virax Biolabs Other Current Liabilities regression line of annual values had r-squared of  0.67 and arithmetic mean of  798,352. View All Fundamentals
 
Other Current Liabilities  
First Reported
2010-12-31
Previous Quarter
63.1 K
Current Value
60 K
Quarterly Volatility
362.6 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Virax Biolabs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Virax Biolabs' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 97.9 K or Interest Expense of 28.3 K, as well as many indicators such as Price To Sales Ratio of 8.96, Dividend Yield of 0.0 or PTB Ratio of 0.29. Virax financial statements analysis is a perfect complement when working with Virax Biolabs Valuation or Volatility modules.
  
Check out the analysis of Virax Biolabs Correlation against competitors.

Latest Virax Biolabs' Other Current Liab Growth Pattern

Below is the plot of the Other Current Liab of Virax Biolabs Group over the last few years. It is Virax Biolabs' Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Virax Biolabs' overall financial position and show how it may be relating to other accounts over time.
Other Current Liab10 Years Trend
Slightly volatile
   Other Current Liab   
       Timeline  

Virax Other Current Liab Regression Statistics

Arithmetic Mean798,352
Geometric Mean615,829
Coefficient Of Variation45.42
Mean Deviation302,061
Median1,024,898
Standard Deviation362,627
Sample Variance131.5B
Range964.9K
R-Value(0.82)
Mean Square Error47.4B
R-Squared0.67
Significance0.0002
Slope(66,126)
Total Sum of Squares1.8T

Virax Other Current Liab History

202460 K
202363.1 K
2022550 K
2021398.9 K
2020654.3 K

About Virax Biolabs Financial Statements

Virax Biolabs investors use historical fundamental indicators, such as Virax Biolabs' Other Current Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Virax Biolabs. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Current Liabilities63.1 K60 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Virax Stock Analysis

When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.